Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Sep 24, 2025; 16(9): 109034
Published online Sep 24, 2025. doi: 10.5306/wjco.v16.i9.109034
Published online Sep 24, 2025. doi: 10.5306/wjco.v16.i9.109034
Advancing gastric cancer treatment: A comprehensive review of hyperthermic intraperitoneal chemotherapy’s role and outcomes
Fabrizio D'Acapito, Massimo Framarini, Paolo Morgagni, Daniela Di Pietrantonio, Giovanni Vittimberga, Valentina Zucchini, Giorgio Ercolani, Department of General and Oncologic Surgery, Morgagni-Pierantoni Hospital, AUSL Romagna, Forli 47121, Emilia-Romagna, Italy
Giorgio Ercolani, Department of Medical and Surgical Sciences, University of Bologna, Bologna 40126, Emilia-Romagna, Italy
Author contributions: D’Acapito F wrote the original draft; Framarini M and Morgagni P contributed to conceptualization, writing, reviewing and editing; Di Pietrantonio D, Vittimberga G, Zucchini V and Ercolani G participated in drafting the manuscript; D’Acapito F, Framarini M, Morgagni P, Di Pietrantonio D, Vittimberga G and Zucchini V done studies initial screening; all authors have read and approved the final version of the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fabrizio D'Acapito, PhD, Consultant, Department of General and Oncologic Surgery, Morgagni-Pierantoni Hospital, AUSL Romagna, Via Carlo Forlanini 34, Forli 47121, Emilia-Romagna, Italy. fabrizioda@gmail.com
Received: April 28, 2025
Revised: May 26, 2025
Accepted: August 8, 2025
Published online: September 24, 2025
Processing time: 148 Days and 9.9 Hours
Revised: May 26, 2025
Accepted: August 8, 2025
Published online: September 24, 2025
Processing time: 148 Days and 9.9 Hours
Core Tip
Core Tip: This systematic review evaluates prospective trials assessing hyperthermic intraperitoneal chemotherapy (HIPEC) in gastric cancer (GC). Therapeutically, HIPEC combined with cytoreductive surgery improves survival in selected patients with peritoneal metastases. Prophylactically, HIPEC reduces peritoneal recurrence after curative gastrectomy in high-risk patients. While promising, outcomes are influenced by heterogeneity in protocols, chemotherapy regimens, and selection criteria. Completeness of cytoreduction remains the strongest predictor of benefit. Future trials should standardize patient selection and HIPEC approaches to clarify its role within multimodal GC treatment strategies.